Roche Phase 1 Clinical Trial of Molecule to Treat Down Syndrome Cognitive Difficulties Announced

The announcement by Roche of a Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome represents a landmark step in research addressing the memory, learning and communication challenges of those with Down syndrome.  Specific information regarding this trial may be found on the Roche Clinical Trial Protocol Registry. The initiation of this clinical trial provides tangible indication of progress in the rapidly advancing area of Down syndrome cognitive research that has received significant non-profit foundation support over the last several years.  Research Down Syndrome is proud to be a leading contributor to this effort.

Please help assure the continued progress of research such as this, and make a donation today!